Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173030 | 0.73 | KCNN4 (0.47) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| SCHEMBL127186 | 0.73 | KCNN4 (0.47) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| SCHEMBL759548 | 0.73 | KCNN4 (0.47) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| Fluoride SCHEMBL28821480 | 0.71 | KCNN4 (0.45) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| Fluoride SCHEMBL28821479 | 0.71 | KCNN4 (0.45) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| SCHEMBL28672611 | 0.71 | KCNN4 (0.45) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| SCHEMBL11439383 | 0.71 | KCNN4 (0.45) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| SCHEMBL28757123 | 0.71 | KCNN4 (0.45) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| SCHEMBL15302663 | 0.71 | KCNN4 (0.45) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 | |
| SCHEMBL8766210 | 0.71 | KCNN4 (0.45) | KCNN4ALDH1A1TSHRMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020147331-A1 | Methods for synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2002-10-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147331-A1 | Methods for synthesis of oligonucleotides | RNGTT, TYMP, PNP | KCNN4 1881/4885ALDH1A1 4843/4885TSHR 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.